Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results at the Society of Urological Oncology Annual Meeting Nov 30, 2016
Heat Biologics to Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results at the International Society for the Study of Lung Cancer Annual Meeting Nov 17, 2016
Heat Biologics to Present Topline HS-410 Phase II Bladder Cancer Results at the Society of Urological Oncology Annual Meeting Nov 16, 2016
Heat Biologics Presents ComPACT Preclinical Data at the Society for Immunotherapy of Cancer Annual Meeting Nov 14, 2016
Heat Biologics Provides Corporate Update and Reports Third Quarter 2016 Financial Results Nov 10, 2016
Heat Biologics to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 7, 2016
Heat Biologics Remains on Track to Achieve  Multiple Topline Data Readouts this Quarter Oct 13, 2016
Heat Biologics Selects Adaptive Biotechnologies to Discover Potential Clinical Biomarkers to Advance Novel Immunotherapies Oct 11, 2016
